Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

H.J. Kruit, Wim; Goey, S.H.; R. T. Monson, J.; A. Stahel, Rolf; Calabresi, F.; Mertelsmann, Roland; E. Holdener, E.; Eggermont, Alexander; L. H. Bolhuis, R.; de Mulder, P.H.M.; Stoter, G.

doi:10.1111/j.1365-2141.1991.tb08128.x

Public

Clinical experience with the combined use of recombinant interleukin‐2 (IL2) and interferon alfa‐2a (IFNα) in metastatic melanoma

Published in British Journal of Haematology • Oct 1, 1991

Authors:

Wim H.J. Kruit

S.H. Goey

J. R. T. Monson

Abstract

A multicentre study of IL2 and IFN alpha has been performed in 58 patients with metastatic melanoma. The scheme consisted of IL2 3.0 BRMP MU/m2/d as a continuous infusion for 4 d combined with subcutaneous administration of IFN alpha 6 MU/m2/d, day 1 + 4. The cycle was repeated every 2 weeks for a m...

Subject

Medicine

Chills

Regimen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!